NCT01658462 2026-03-16
VAROCE
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
34 trialsNCT02863055 2025-09-19
NEMO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02730416 2025-07-29
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT02299141 2025-06-24
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02496585 2025-04-16
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02009579 2024-08-07
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Belgian Gynaecological Oncology Group
Phase 2 Completed
NCT03287947 2022-08-09
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02665143 2022-04-08
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Yale University
Phase 2 Completed
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT02568449 2021-12-09
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02808247 2021-09-20
ANITA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02531737 2021-08-10
REFRACT
University Hospital, Limoges
Phase 2 Completed
NCT02234596 2021-01-25
Nintedanib in Patients With Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01788982 2020-07-31
Nintedanib(BIBF1120) in Thyroid Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02452463 2020-04-06
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01362361 2019-09-19
AIO-KRK-0111
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Completed
NCT02389764 2019-07-17
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01610869 2019-05-29
METRO-BIBF
University College, London
Phase 2 Completed
NCT01669798 2018-10-16
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Duke University
Phase 2 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT02182063 2017-12-28
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT01225887 2017-10-09
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT01441297 2017-08-25
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT01948141 2017-06-08
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Roswell Park Cancer Institute
Phase 2 Completed
NCT02856867 2017-05-09
MEGAN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00710762 2016-08-15
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00987935 2016-03-10
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Boehringer Ingelheim
Phase 2 Completed
NCT02558387 2015-11-20
Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Samsung Medical Center
Phase 2 Unknown
NCT02278978 2015-05-12
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Unknown
NCT00904839 2015-02-04
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01380782 2014-08-18
BIBF 1120 for Recurrent High-Grade Gliomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01251484 2012-10-04
BIBF 1120 in Recurrent Glioblastoma Multiforme
Rigshospitalet, Denmark
Phase 2 Completed